
ORIGINAL ARTICLE

Comparative toxicity study of 2,4,6-trinitrophenol (picric acid) in newborn and young rats

Mika Takahashi¹, Hidehiro Ogata², Hiroyuki Izumi², Kotaro Yamashita³, Masato Takechi³, Mutsuko Hirata-Koizumi¹, Eiichi Kamata¹, Ryuichi Hasegawa¹, and Makoto Ema¹

¹National Institute of Health Sciences, Tokyo, ²Panapharm Laboratories, Uto, and ³Kashima Laboratory, Mitsubishi Chemical Safety Institute, Kashima, Japan

ABSTRACT The toxicity of oral 2,4,6-trinitrophenol (TNP) was determined in newborn rats, and compared with that in young rats. In newborn rats, males and females were given TNP at 0, 16.3, 81.4 or 407 mg/kg per day on postnatal days (PND) 4–17 for the dose-finding study, and at 0, 4.1, 16.3 or 65.1 mg/kg per day on PND 4–21 for the main study. Deaths, lower body weight (BW) and behavioral changes were found at 81.4 and 407 mg/kg per day in the dose-finding study, and lower BW was observed in males at 65.1 mg/kg per day during the dosing period of the main study. In young rats, 5-week-old males and females were given TNP at 0, 20, 100 or 500 mg/kg per day for 14 days as the dose-finding study and at 0, 4, 20 or 100 mg/kg per day for 28 days as the main study. Deaths were observed at 500 mg/kg per day in the dose-finding study. Deaths or changes in BW were not found at 100 mg/kg per day or less. At 100 mg/kg per day, hemolytic anemia and testicular toxicity were found. In conclusion, toxicity profiles induced by TNP were markedly different between newborn and young rats.

Key Words: 2, 4, 6-trinitrophenol, newborn rats, picric acid, repeated-dose toxicity, young rats

INTRODUCTION

The adverse effects of environmental chemicals including endocrine disruptors on not only contemporary but also future generations are causing increasing concern. The possible toxic effect of chemicals on fetuses and newborns has

aroused great concern among the public, and the protection of fetuses and newborns has become a major scientific and political issue.

Comprehensive statements for children's health, considering their special vulnerability to certain toxic substances, are shown in the US Environmental Protection Agency Children's Environmental Health Yearbook (US EPA 1998). Infants and young children have greater respiratory and circulatory flow rates, as well as energy and fluid requirements than adults, giving rise to a greater potential for respiratory and intestinal exposure to chemicals per unit body weight (BW) (WHO 1986). Children live close to the ground because of their behavioral patterns of play and their height and perform hand-to-mouth activities, which would expose them to much larger amounts of pollutants in dust and soil (US EPA 1998). However, children could be less sensitive than adults to some chemicals (NRC 1993) because infants have more extracellular water that is the only avenue connecting cells with the outside world (Fomon *et al.* 1982), enough amounts of toxic metabolites are not produced in infants due to their immature metabolic capacities (Kearns & Reed 1989), or the developing brain has increased plasticity.

Because of these unique characteristics, children react differently from adults. Differences in susceptibility to toxicants between children and adults may result from a combination of toxicokinetic, toxicodynamic and exposure factors (Schwenk *et al.* 2002). The potential toxic effects of chemicals on children cannot be anticipated using data on adults, and a data set on exposed children is essential for the assessment of children's health. Although gathering information on the toxicity of chemicals in newborns is very important to evaluate children's health, toxicity data on chemical compounds in newborns are limited.

We have already reported the differences in the susceptibility to toxicities of chemicals between newborn and young rats (Koizumi *et al.* 2001, Koizumi 2002, Koizumi 2003;

Correspondence: Makoto Ema, DVM, PhD, Division of Risk Assessment, Biological Safety Research Center, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. Email: ema@nihs.go.jp

Received August 13, 2004; revised and accepted August 30, 2004.

Fukuda *et al.* 2004). We demonstrated that the toxic response in newborn rats was at most four times (4-nitrophenol and 2,4-dinitrophenol), approximately three times (3-aminophenol), and three to four times (3-methylphenol) higher than that in young rats. The toxicological profiles of 4-nitrophenol (Koizumi *et al.* 2001), 2,4-dinitrophenol (Koizumi *et al.* 2001), 3-aminophenol (Koizumi *et al.* 2002), and 3-methylphenol (Koizumi *et al.* 2003) were similar in newborn rats and young rats. The nephrotoxicity of tetrabromobisphenol A was specific for newborn rats (Fukuda *et al.* 2004).

2,4,6-Trinitrophenol (TNP) was listed in the Organisation for Economic Co-operation and Development (OECD) High Production Volume Chemical Table in 1999, meaning that it is produced at levels greater than 1000 tonnes per year in at least one OECD member country. TNP is known as picric acid, has a yellow color and is explosive. This compound is used in the production of gunpowder, fireworks, agricultural chemicals and dyes, and is widely used in industry, by the military, and as a research/clinical chemistry reagent. Much of the human toxicity data showed that exposure to picric acid was primarily through inhalation of dust or through skin contact (Wyman *et al.* 1992). This chemical caused irritation of eyes, a transient yellowish appearance, and skin sensitization in humans (Health Council of the Netherlands 2002). Wyman *et al.* (1992) investigated the acute toxicity, distribution, and metabolism of TNP using Fischer 344 rats. The values of oral LD50 in male and female rats were 290 and 200 mg/kg, respectively. TNP was found to bring about severe acidosis during acute intoxication. Recently, a 28-day repeat dose oral toxicity study of this compound in young rats was conducted as part of the Japanese Existing Chemical Safety Program (MHLW 2001), in which the no observed effect level (NOEL) and toxicity profile of chemicals were evaluated.

In the present paper, we re-evaluated the toxicity of TNP in young rats (MHLW 2001), determined the toxicity of TNP in newborn rats, and compared the findings.

MATERIALS AND METHODS

Chemicals

TNP (2,4,6-trinitrophenol, CAS. no. 88-89-1, purity: 81.4%) was obtained from Mitsui Chemicals (Tokyo, Japan) and suspended in a 0.5% CMC-Na (carboxymethyl cellulose sodium salt; Nacalai Tesque, Kyoto, Japan or Iwai Chemicals, Tokyo, Japan) aqueous solution mixed with 0.1% Tween-80 (polyoxyethylene sorbitan monooleate; Nacalai Tesque, Kyoto, Japan or Difco Laboratories, Detroit, USA).

Animals

In the newborn rat study, pregnant SPF Crj:CD(SD)IGS rats (gestation day 13) were purchased from Atsugi Breeding

Center, Charles River Japan (Yokohama, Japan) and allowed to deliver spontaneously. The animals were maintained in an environmentally controlled room at $24 \pm 2^\circ\text{C}$ with a relative humidity of $55 \pm 10\%$ and a 12:12 h light/dark cycle. Newborn rats were separated from dams on postnatal day (PND) 3.

In the young rat study, 4-week-old males and females of the same strain were purchased from the same farm. The animals were maintained in an environmentally controlled room at $22 \pm 2^\circ\text{C}$ with a relative humidity of $55 \pm 15\%$ and a 12:12 h light/dark cycle.

All animals in the newborn and young rat studies were allowed free access to a sterilized basal diet (MF, Oriental Yeast, Tokyo, Japan) and water. Rats were euthanized by exsanguination under anesthesia using sodium pentobarbital in the newborn rat study and sodium thiopental in the young rat study.

Repeated dose study in newborn rats

Time schedule of the newborn rat studies is shown in Figure 1.

Dose-finding study


Sixteen males and 16 females were randomly selected and assigned to four dose groups, including a control group. Four foster mothers were used. One foster mother suckled the four males and four females. Pups (4/sex per dose) were given TNP by gavage at 0, 16.3, 81.4 or 407 mg (as TNP)/kg per day on PND 4–17 (14 days) and killed on PND 18 after overnight starvation. General condition, BW, hematology, blood biochemistry, necropsy, and organ weights were examined.

Main study

Forty-eight males and 48 females for two autopsy groups (the ends of the dosing period and recovery-maintenance period) were randomly selected and assigned to four dose groups, including a control group. Twelve foster mothers were used. One foster mother suckled the four males and four females up to weaning on PND 22. After weaning, rats of the recovery-maintenance group were individually maintained for 9 weeks. Pups (6/sex per dose) were given TNP by gavage at 0, 4.1, 16.3 or 65.1 mg (as TNP)/kg per day on PND 4–21 (18 days), and killed after overnight starvation following the last treatment. The dosage levels were determined based on the results of the dose-finding study in newborn rats. Recovery-maintenance groups (6/sex per dose) given the same dosages were maintained for 9 weeks without chemical treatment and fully examined at 12 weeks, almost the same age as at the end of the recovery period of the main study of young rats.

General condition was observed two times per day (before and after administration) for pups (separated from each foster mother) and foster mothers during the dosing period, and

Newborn rat study



Young rat study




Fig. 1 Time schedule of the newborn and young rat studies.

daily for pups during the recovery-maintenance period. BW and food consumption were measured more than two times per week. All pups were examined for developmental landmarks; pinna detachment on PND 4, piliation on PND 8, incisor eruption on PND 10, gait and eye opening on PND 15, testes descent on PND 21, preputial separation on PND 42, and/or vaginal opening on PND 42. BW was measured on the day of testes descent, preputial separation and/or vaginal opening. All pups were examined for the assessment of reflex ontogeny; surface righting reflex and ipsilateral flexor reflex on PND 5, visual placing response on PND 16, and Preyer's reflex on PND 28.

In urinalysis, color, pH, occult blood, protein, glucose, ketone bodies, bilirubin, urobilinogen, urine sediment, specific gravity, osmotic pressure and volume of urine were examined only at the end of the recovery-maintenance period. Rats were killed on PND 22 or PND 85. On the day that the rats were killed, blood was collected from the abdominal vein. Hematological parameters, such as the red blood cell count (RBC), hemoglobin (Hb), hematocrit (Ht), mean corpuscular volume (MCV), mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration (MCHC), white blood cell count (WBC), platelet counts, reticulocyte ratio (Ret), differential leukocyte count, and blood clotting parameters, such as prothrombin time and activated thromboplastin time, were determined. The blood biochemical parameters, such as the total protein, albumin, albumin-globulin ratio, glucose, total cholesterol, triglycerides, total bilirubin, urea nitrogen, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT),

γ -glutamyl transpeptidase (γ -GTP), alkaline phosphatase, phospholipids, calcium, inorganic phosphorus, sodium, potassium and chloride levels in serum, were also determined. After a gross examination, the brain, pituitary gland, heart, thymus, liver, kidneys, spleen, adrenals, thyroids, lungs, testes, epididymides and/or ovaries were weighed. The organs were fixed with 10% buffered formalin-phosphate (2.5% glutaraldehyde's pre-fixation for the eyes, Bouin's pre-fixation for the testes and epididymis) and paraffin sections were routinely prepared and stained with hematoxylin-eosin for microscopic examination. The study using newborn rats was conducted at Panapharm Laboratories Co., Ltd. (Uto, Japan) under Good Laboratory Practice (GLP) conditions (OECD 1981; MHW 1988).

Repeated dose study in young rats

Time schedule of the young rat studies is shown in Figure 1.

Dose-finding study

Five-week-old rats (3/sex per dose) were given TNP by gavage at 0, 20, 100 or 500 mg (as TNP)/kg per day for 14 days and killed the day following the last administration after overnight starvation. General condition, BW and food consumption, hematology, necropsy, and organ weights were examined.

Main study

Five-week-old rats (6/sex per dose) were given TNP by gavage at 0, 4, 20 or 100 mg (as TNP)/kg per day for 28 days and killed after overnight starvation following the last

treatment. The dosage levels were determined based on the results of the dose-finding study in young rats. Recovery groups (0 or 100 mg/kg per day) (6/sex per dose) were maintained for 2 weeks without chemical treatment and fully examined at 11 weeks of age. Rats were examined for general condition, BW, food consumption, urinalysis, hematology and blood biochemistry, necropsy findings, organ weights and histopathological findings. The study using young rats was conducted at Kashima Laboratory, Mitsubishi Chemical Safety Institute Ltd. (Kashima, Japan) under GLP conditions (MHW 1988; OECD 1997).

Statistical analysis

Continuous data were analyzed with Bartlett's test for homogeneity of variance. If the data were homogeneous, Dunnett's test was conducted for group comparisons between control and individual TNP-treated groups. If not homogeneous, the data were analyzed using Steel's test. Quantitative data for histopathology were analyzed with Mann-Whitney's *U*-test or Fisher's exact test. In the newborn rat study, the chi-square test was conducted for physical and sexual development and reflex ontogeny. The 0.05 or 0.01 level of probability was used as the criterion for significance.

RESULTS

Repeated dose study in newborn rats (dose-finding study)

Death occurred at 81.4 mg/kg per day in one male on day 3 of the dosing period, two females on days 6 and 7 of the dosing period, and at 407 mg/kg per day in all rats by day 4 of the dosing period. In these dead rats, hypoactivity, bradypnea and hypothermia were observed. Only hypoactivity was found in surviving rats at 81.4 mg/kg per day on days 3, 5, or 8 of the dosing period. Yellowish fur was observed in all TNP-treated rats.

A significantly lower BW (max. 16% decreased) in males, and suppression of weight gain (max. 35% decreased) in females were noted at 81.4 mg/kg per day. The organ weights are summarized in Table 1. At 81.4 mg/kg per day, a significantly higher relative weight of the liver (13% increased) and lower relative weight of the kidney (14% decreased) were observed in males.

No consistent changes related to the administration of TNP in hematological or blood biochemical parameters or necropsy findings were found at any doses.

Repeated dose study in newborn rats (main study)

There were no deaths throughout the experimental period in males and females, even at 65.1 mg/kg per day. Yellowish fur was observed in all TNP-treated rats. A significantly lower BW (max. 7% decreased) was found in males on days 4 and 8 of the dosing period at 65.1 mg/kg per day. During

the recovery-maintenance period, no dose-dependent effects on BW and food consumption were observed.

No toxicological effects of TNP on physical development, reflex ontogeny, and sexual maturation were detected at any doses in the newborn rat study.

The organ weights are summarized in Table 1. Significantly higher relative weights of the liver in males and females (13 and 12% increased, respectively) were observed at 65.1 mg/kg per day.

No consistent changes related to the administration of TNP were found in hematological or biochemical parameters, urinalysis or histopathological findings.

Repeated dose study in young rats (dose-finding study)

All male rats and one female rat at 500 mg/kg per day died by day 2 of the dosing period. No death was found at 20 and 100 mg/kg per day. Yellowish fur was observed in all TNP-treated rats. BW of males and females at 20 and 100 mg/kg per day were not significantly different from controls during the dosing period.

The results of hematological examinations are summarized in Table 2. Significantly lower values of Hb and Ht, and a higher value of Ret were detected in females at 100 mg/kg per day.

The organ weights are summarized in Table 3. At 100 mg/kg per day, a significantly higher value of relative spleen weight (14% increased) in males, and a significantly higher value of relative liver weight (18% increased) in females were observed.

Repeated dose study in young rats (main study)

There were no deaths throughout the experimental period even at 100 mg/kg per day. Yellowish fur was observed in all TNP-treated rats. A yellowish color change of urine was also found in all TNP-treated groups during the dosing period and this coloration disappeared during the recovery period. BW of males and females in the TNP-treated groups were not significantly different from controls during the dosing and recovery periods. No consistent changes in food consumption were found in the TNP-treated groups.

The results of hematological examinations are summarized in Table 2. Significantly higher values of WBC and Ret and lower values of RBC and Hb were observed in males at 100 mg/kg per day. At this dose, significantly higher values of WBC, MCV and Ret, and lower values of RBC, Hb and MCHC were also found in females.

The organ weights are summarized in Table 3. Significantly higher values of relative liver weight (12% increased) and relative spleen weight (45% increased) and significantly lower value of relative epididymides weight (21% decreased) were observed in males at 100 mg/kg per day at the end of the dosing period. A significantly lower value of relative epididymides weight at 100 mg/kg per day was also

Table 1 Organ weights in the newborn rat study of 2,4,6-trinitrophenol

| Dose (mg/kg per day) | Dose-finding study† | | | | Main study‡ | | | |
|----------------------|---------------------|---------------|-----------------|---------------|---------------|---------------|-----------------|---|
| | 0 | 16.3 | 81.4 | 0 | 4.1 | 16.3 | 65.1 | |
| Males | | | | | | | | |
| No. animals | 4 | 4 | 3 | 6 | 6 | 6 | 6 | 6 |
| Body weight§ (g) | 48.9 ± 3.7 | 47.7 ± 2.6 | 42.3 ± 2.0* | 63.4 ± 4.9 | 63.0 ± 2.8 | 63.7 ± 5.7 | 61.8 ± 4.8 | |
| Liver (g) | 1.73 ± 0.14 | 1.67 ± 0.13 | 1.70 ± 0.13 | 2.69 ± 0.22 | 2.74 ± 0.14 | 2.79 ± 0.24 | 2.97 ± 0.38 | |
| (g/100 g BW) | (3.55 ± 0.10) | (3.49 ± 0.12) | (4.01 ± 0.13)** | (4.25 ± 0.16) | (4.35 ± 0.12) | (4.38 ± 0.08) | (4.79 ± 0.28)** | |
| Spleen (g) | 0.21 ± 0.04 | 0.21 ± 0.02 | 0.17 ± 0.01 | 0.34 ± 0.07 | 0.35 ± 0.06 | 0.38 ± 0.04 | 0.37 ± 0.06 | |
| (g/100 g BW) | (0.44 ± 0.07) | (0.45 ± 0.05) | (0.40 ± 0.03) | (0.54 ± 0.07) | (0.56 ± 0.08) | (0.60 ± 0.05) | (0.60 ± 0.05) | |
| Kidneys (g) | 0.58 ± 0.03 | 0.56 ± 0.04 | 0.43 ± 0.05** | 0.74 ± 0.12 | 0.73 ± 0.08 | 0.77 ± 0.03 | 0.73 ± 0.12 | |
| (g/100 g BW) | (1.18 ± 0.04) | (1.17 ± 0.05) | (1.02 ± 0.08)** | (1.16 ± 0.12) | (1.16 ± 0.09) | (1.21 ± 0.10) | (1.18 ± 0.12) | |
| Epididymides (mg) | - | - | - | 57.6 ± 4.6 | 55.4 ± 6.0 | 57.6 ± 7.3 | 50.3 ± 3.7 | |
| (mg/100 g BW) | - | - | - | (91.1 ± 6.9) | (87.9 ± 7.2) | (91.3 ± 16.4) | (81.9 ± 7.9) | |
| Testes (mg) | - | - | - | 326 ± 47 | 302 ± 27 | 319 ± 22 | 295 ± 20 | |
| (mg/100 g BW) | - | - | - | (513 ± 54) | (479 ± 26) | (504 ± 44) | (478 ± 27) | |
| Females | | | | | | | | |
| No. animals | 4 | 4 | 2 | 6 | 6 | 6 | 6 | |
| Body weight§ (g) | 45.2 ± 2.2 | 47.5 ± 3.1 | 38.6 | 59.0 ± 3.3 | 59.6 ± 2.3 | 57.0 ± 4.6 | 58.8 ± 5.3 | |
| Liver (g) | 1.57 ± 0.08 | 1.72 ± 0.09 | 1.64 | 2.46 ± 0.22 | 2.44 ± 0.24 | 2.33 ± 0.25 | 2.75 ± 0.28 | |
| (g/100 g BW) | (3.48 ± 0.25) | (3.62 ± 0.10) | (4.23) | (4.18 ± 0.35) | (4.09 ± 0.29) | (4.09 ± 0.19) | (4.67 ± 0.19)* | |
| Spleen (g) | 0.20 ± 0.03 | 0.20 ± 0.04 | 0.17 | 0.32 ± 0.04 | 0.33 ± 0.04 | 0.29 ± 0.05 | 0.37 ± 0.05 | |
| (g/100 g BW) | (0.43 ± 0.04) | (0.43 ± 0.06) | (0.44) | (0.54 ± 0.05) | (0.55 ± 0.07) | (0.51 ± 0.08) | (0.62 ± 0.03) | |
| Kidneys (g) | 0.55 ± 0.02 | 0.57 ± 0.05 | 0.43 | 0.69 ± 0.05 | 0.69 ± 0.06 | 0.66 ± 0.06 | 0.70 ± 0.05 | |
| (g/100 g BW) | (1.22 ± 0.06) | (1.20 ± 0.06) | (1.12) | (1.17 ± 0.09) | (1.16 ± 0.08) | (1.16 ± 0.10) | (1.20 ± 0.06) | |

†Rats were killed on postnatal day (PND) 18; ‡rats were killed on PND 22; §body weight (BW) after overnight starvation follow the last dosing. Values are given as the mean ± SD. * $P < 0.05$ and ** $P < 0.01$ indicate significantly different from control group. -, no data.

Table 2 Hematological parameters in the young rat study of 2,4,6-trinitrophenol

| Dose (mg/kg per day) | Dose-finding study† | | | Main study‡ | | | |
|-----------------------------------|---------------------|----------------|------------------|----------------|----------------|----------------|------------------|
| | 0 | 20 | 100 | 0 | 4 | 20 | 100 |
| Males | | | | | | | |
| No. animals | 3 | 3 | 3 | 6 | 6 | 6 | 6 |
| WBC ($\times 10^3/\mu\text{L}$) | 117 \pm 26 | 94 \pm 20 | 108 \pm 21 | 93 \pm 14 | 98 \pm 14 | 112 \pm 22 | 146 \pm 38** |
| RBC ($\times 10^6/\mu\text{L}$) | 682 \pm 13 | 651 \pm 24 | 646 \pm 32 | 720 \pm 32 | 720 \pm 13 | 739 \pm 34 | 661 \pm 52* |
| Hb (g/dL) | 14.0 \pm 0.6 | 13.8 \pm 0.2 | 13.8 \pm 0.6 | 14.3 \pm 0.3 | 14.6 \pm 0.5 | 14.8 \pm 0.7 | 13.4 \pm 0.7* |
| Ht (%) | 40.9 \pm 1.4 | 41.3 \pm 1.5 | 40.9 \pm 2.7 | 40.9 \pm 1.0 | 41.5 \pm 1.8 | 42.6 \pm 1.4 | 39.1 \pm 2.2 |
| MCV (fL) | 60.0 \pm 3.1 | 63.4 \pm 1.1 | 63.3 \pm 1.7 | 56.8 \pm 1.6 | 57.7 \pm 2.3 | 57.8 \pm 2.3 | 59.3 \pm 2.7 |
| MCHC (%) | 34.2 \pm 0.3 | 33.5 \pm 1.0 | 33.7 \pm 0.9 | 35.0 \pm 0.7 | 35.2 \pm 0.6 | 34.8 \pm 0.6 | 34.1 \pm 0.5 |
| Ret (‰) | 59.8 \pm 5.6 | 61.1 \pm 3.7 | 72.6 \pm 8.2 | 31.4 \pm 1.4 | 29.8 \pm 4.1 | 31.6 \pm 3.8 | 54.7 \pm 7.6** |
| Females | | | | | | | |
| No. animals | 3 | 3 | 3 | 6 | 6 | 6 | 6 |
| WBC ($\times 10^3/\mu\text{L}$) | 82 \pm 7 | 70 \pm 12 | 98 \pm 31 | 67 \pm 18 | 79 \pm 27 | 73 \pm 15 | 123 \pm 33** |
| RBC ($\times 10^6/\mu\text{L}$) | 711 \pm 6 | 690 \pm 31 | 639 \pm 47 | 706 \pm 30 | 711 \pm 47 | 713 \pm 41 | 608 \pm 19** |
| Hb (g/dL) | 14.6 \pm 0.1 | 14.5 \pm 0.3 | 13.5 \pm 0.7* | 14.2 \pm 0.5 | 14.3 \pm 0.5 | 14.3 \pm 0.6 | 12.6 \pm 0.3** |
| Ht (%) | 42.4 \pm 0.3 | 41.4 \pm 0.6 | 38.5 \pm 1.7** | 39.3 \pm 1.2 | 40.3 \pm 1.9 | 40.3 \pm 1.8 | 37.3 \pm 0.9 |
| MCV (fL) | 59.6 \pm 0.8 | 60.0 \pm 3.6 | 60.3 \pm 1.8 | 55.8 \pm 0.9 | 56.9 \pm 3.4 | 56.6 \pm 1.7 | 61.4 \pm 2.4** |
| MCHC (%) | 34.5 \pm 0.4 | 35.2 \pm 0.3 | 35.0 \pm 0.3 | 36.2 \pm 0.9 | 35.6 \pm 0.6 | 35.6 \pm 0.7 | 33.9 \pm 0.3** |
| Ret (‰) | 37.6 \pm 1.5 | 39.6 \pm 6.9 | 56.3 \pm 3.6** | 25.5 \pm 4.6 | 25.2 \pm 1.0 | 24.1 \pm 3.3 | 65.5 \pm 5.9* |

†Rats were killed at 7 weeks of age; ‡rats were killed at 9 weeks of age. Values are given as the mean \pm SD. * $P < 0.05$ and ** $P < 0.01$ indicate significantly different from control group. Hb, hemoglobin; Ht, hematocrit; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; RBC, red blood cell count; Ret, reticulocyte ratio; WBC, white blood cell count.

Table 3 Organ weights in the young rat study of 2,4,6-trinitrophenol

| Dose (mg/kg per day) | Dose-finding study† | | | Main study‡ | | | Main study (at the end of recovery period)§ | | |
|-------------------------|---------------------|---------------|----------------|---------------|---------------|---------------|--|---------------|-----------------|
| | 0 | 20 | 100 | 0 | 4 | 20 | 100 | 0 | 100 |
| Males | | | | | | | | | |
| No. animals | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 6 | 6 |
| Body weight¶ (g) | 267 ± 15 | 257 ± 7 | 276 ± 9 | 374 ± 12 | 380 ± 31 | 384 ± 35 | 367 ± 27 | 449 ± 20 | 529 ± 43 |
| Liver (g) | 10.8 ± 0.4 | 10.9 ± 0.7 | 12.2 ± 0.2* | 14.2 ± 1.3 | 14.0 ± 0.9 | 14.4 ± 1.8 | 15.6 ± 1.1 | 15.5 ± 1.1 | 14.8 ± 2.2 |
| (g/100 g BW) | (4.04 ± 0.12) | (4.26 ± 0.39) | (4.43 ± 0.17) | (3.79 ± 0.31) | (3.69 ± 0.19) | (3.73 ± 0.23) | (4.24 ± 0.24)* | (3.46 ± 0.22) | (3.45 ± 0.20) |
| Spleen (g) | 0.77 ± 0.10 | 0.75 ± 0.03 | 0.91 ± 0.07 | 0.82 ± 0.08 | 0.76 ± 0.08 | 0.89 ± 0.19 | 1.18 ± 0.16** | 0.86 ± 0.09 | 0.84 ± 0.07 |
| (g/100 g BW) | (0.29 ± 0.03) | (0.29 ± 0.02) | (0.33 ± 0.02)* | (0.22 ± 0.02) | (0.20 ± 0.02) | (0.23 ± 0.03) | (0.32 ± 0.03)** | (0.19 ± 0.02) | (0.20 ± 0.01) |
| Kidneys (g) | 2.29 ± 0.25 | 2.12 ± 0.16 | 2.39 ± 0.12 | 2.62 ± 0.13 | 2.57 ± 0.13 | 2.81 ± 0.33 | 2.72 ± 0.13 | 2.85 ± 0.23 | 2.92 ± 0.31 |
| (g/100 g BW) | (0.86 ± 0.06) | (0.83 ± 0.04) | (0.87 ± 0.02) | (0.70 ± 0.03) | (0.68 ± 0.05) | (0.73 ± 0.06) | (0.74 ± 0.03) | (0.64 ± 0.05) | (0.68 ± 0.04) |
| Testes (g) | - | - | - | 3.08 ± 0.32 | 3.09 ± 0.19 | 3.13 ± 0.25 | 3.29 ± 0.35 | 3.30 ± 0.09 | 2.64 ± 1.07 |
| (g/100 g BW) | - | - | - | (0.82 ± 0.09) | (0.82 ± 0.06) | (0.82 ± 0.05) | (0.90 ± 0.05) | (0.74 ± 0.03) | (0.61 ± 0.22) |
| Epididymides (g) | - | - | - | 0.82 ± 0.06 | 0.78 ± 0.06 | 0.78 ± 0.07 | 0.63 ± 0.10** | 1.10 ± 0.07 | 0.82 ± 0.11** |
| (g/100 g BW) | - | - | - | (0.22 ± 0.02) | (0.21 ± 0.02) | (0.20 ± 0.01) | (0.17 ± 0.03)** | (0.24 ± 0.01) | (0.20 ± 0.03)** |
| Female | | | | | | | | | |
| No. animals | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 6 | 6 |
| Body weight¶ (g) | 165 ± 9 | 172 ± 4 | 175 ± 8 | 242 ± 19 | 241 ± 17 | 237 ± 29 | 233 ± 14 | 283 ± 18 | 270 ± 19 |
| Liver (g) | 6.4 ± 0.8 | 6.7 ± 0.1 | 8.0 ± 0.6* | 8.2 ± 0.7 | 8.0 ± 0.8 | 8.2 ± 1.5 | 9.7 ± 1.2 | 9.3 ± 0.7 | 9.3 ± 1.1 |
| (g/100 g BW) | (3.85 ± 0.28) | (3.90 ± 0.07) | (4.54 ± 0.23)* | (3.38 ± 0.11) | (3.32 ± 0.15) | (3.45 ± 0.19) | (4.16 ± 0.27)** | (3.27 ± 0.15) | (3.43 ± 0.27) |
| Spleen (g) | 0.49 ± 0.13 | 0.45 ± 0.13 | 0.56 ± 0.05 | 0.51 ± 0.08 | 0.58 ± 0.05 | 0.54 ± 0.08 | 0.98 ± 0.12** | 0.60 ± 0.10 | 0.63 ± 0.09 |
| (g/100 g BW) | (0.30 ± 0.06) | (0.26 ± 0.08) | (0.32 ± 0.01) | (0.21 ± 0.04) | (0.24 ± 0.02) | (0.23 ± 0.20) | (0.42 ± 0.05)** | (0.21 ± 0.02) | (0.23 ± 0.02) |
| Kidneys (g) | 1.40 ± 0.03 | 1.45 ± 0.13 | 1.52 ± 0.17 | 1.77 ± 0.16 | 1.73 ± 0.20 | 1.67 ± 0.20 | 1.86 ± 0.17 | 1.82 ± 0.12 | 1.86 ± 0.10 |
| (g/100 g BW) | (0.85 ± 0.03) | (0.84 ± 0.07) | (0.87 ± 0.11) | (0.74 ± 0.07) | (0.71 ± 0.04) | (0.71 ± 0.05) | (0.80 ± 0.06) | (0.65 ± 0.06) | (0.69 ± 0.06) |

†Rats were killed at 7 weeks of age; ‡rats were killed at 9 weeks of age; §rats were killed at 11 weeks of age; ¶body weight (BW) after overnight starvation following the last dosing. Values are given as the mean ± SD. * $P < 0.05$ and ** $P < 0.01$ indicate significantly different from control group. -, no data.

noted at the end of the recovery period. At this dose in females, significantly higher values of relative liver weight (23% increased) and relative spleen weight (100% increased) were noted. No other changes related to the administration of TNP were found.

At the end of the dosing period, enlargement of the spleen and erosion or ulcers in the cecum were observed in males and females at 100 mg/kg per day. Small testes were found at 100 mg/kg per day at the end of the recovery period.

The histopathological findings are summarized in Table 4. Significant changes were noted at 100 mg/kg per day. Spleens with the development of a germinal center and extramedullary hematopoiesis were observed in males and females at 100 mg/kg per day at the end of the dosing period. Hemosiderin deposition in the spleen was found in males and females at 100 mg/kg per day at the end of the dosing and recovery periods. Centrilobular hypertrophy of hepatocytes in the liver and ulcers in the cecum were observed in males and females at 100 mg/kg per day at the end of the dosing period. Testes with diffuse atrophy of seminiferous tubules were noted at 100 mg/kg per day at the end of the dosing period, and severe atrophy was observed at the end of the recovery period. A decreased number of sperm and lumen with cell debris were observed in the epididymides at 100 mg/kg per day at the end of the dosing and recovery periods.

There were no consistent changes related to the administration of TNP in biochemical parameters for blood or urine.

DISCUSSION

In the present study, we re-evaluated the toxicity of TNP in young rats in terms of the NOAEL and toxicity profile, and determined the toxicity of this chemical in newborn rats, then compared the toxicity in newborn and young rats. We showed here that TNP had a markedly different toxicity profile between newborn and young rats.

As for the yellowish fur in all newborn and young rats treated with TNP, their hair roots and skin showed no anomalies therefore it does not seem to be an adverse effect of TNP.

In the newborn rat study, the major toxicity was death and low BW without any other toxicologically significant changes at 81.4 mg/kg per day in the dose-finding study. Deaths occurred in days 3–7 after dosing onset. At the lower dose, 65.1 mg/kg per day in the main study, a slightly low BW in males was observed only at 4 and 8 days after dosing onset. This slight and transient loss of BW might be accepted as having no toxicological significance in general, but we considered it to be closely related to the death that occurred at the higher dose, 81.4 mg/kg per day, because death and low BW were observed on the same days after dosing onset (late in the first week). Slight changes in relative liver and

kidney weights were observed but not considered toxicologically significant because there were no changes in biochemical and urinary parameters, or histopathological findings. Based on low BW at 65.1 mg/kg per day in males, the NOAEL for newborn rats was considered 16.3 mg/kg per day.

In the MHLW (2001) report, the NOEL was concluded 4 mg/kg per day based on yellowish fur and decreased level of urine potassium in young rats. The major adverse effects of TNP were hemolytic anemia and testicular toxicity without death or changes of BW at 100 mg/kg per day in the main study with young rats. No toxic effects were detected at 20 mg/kg per day or less after administration of TNP in the dose-finding or main study with young rats. Based on these findings, we re-evaluated that the NOAEL for young rats was considered 20 mg/kg per day.

TNP, at 81.4 mg/kg per day or more, caused behavioral changes in the newborn rat study but not in the young rat study at 100 mg/kg per day. The immature blood–brain barrier in newborn rats may explain these phenomena. The diffusional resistance is primarily the result of tight junctions between endothelial cells, the absence of pores within the cells and a thicker, more developed basement membrane surrounding each cell (Reese & Karnovsky 1967; Scheuplein *et al.* 2002). In rats, capillary diffusion decreases during postnatal weeks 3–4 (Bär & Wolff 1972).

Histopathological and hematological examinations revealed hemolytic anemia as evidenced by reductions of RBC and Hb and hemosiderin deposition and extramedullary hematopoiesis in spleen at 100 mg/kg per day in the young rat study, but not in the newborn rat study at 81.4 mg/kg per day. Hemolytic anemia can be induced by various kinds of medicines and chemicals including some aromatic amines due to oxidation (Bloom & Brandt 2001). TNP may not be the causal substance because it occurred in young rats but not in newborn rats whose metabolic capacity is immature, such as lower total cytochrome P-450 levels (Imaoka *et al.* 1991). Thus, TNP metabolites might be the cause. As for absorption and excretion of TNP in rats, Wyman *et al.* (1992) reported that fasted rats would absorb about 60% of orally treated TNP in 24 h and the main metabolite was picramic acid following oral dosing in rats. Picramic acid, a type of aromatic amine, would be the most likely candidate, although there is no evidence of hemolytic anemia caused by picramic acid. The information together suggests that the absence of hemolytic anemia in newborn rats may be due to insufficient amounts of picramic acid produced as a metabolite of TNP.

As for the testicular toxicity, degenerating primary spermatocytes and alterations in Sertoli cells were caused by di(2-ethylhexyl) phthalate in 5-week-old, but not 3-week-old, rats (Sjöberg *et al.* 1985). TNP also had toxic effects on the testes and epididymides in young rats, but not in

Table 4 Histopathological findings at the end of dosing and recovery periods in the young rat main study of 2,4,6-trinitrophenol

| Dose (mg/kg per day) | Dosing period† | | | | Recovery period‡ | | |
|---|----------------|---|----|-----|------------------|-----|---|
| | 0 | 4 | 20 | 100 | 0 | 100 | |
| Males | | | | | | | |
| No. animals examined | 6 | 6 | 6 | 6 | 6 | 6 | |
| Spleen | | | | | | | |
| Development, germinal center | + | 0 | 0 | 5 | * | 0 | 0 |
| Extramedullary hematopoiesis, erythrocyte | + | 0 | 0 | 6 | ** | 0 | 0 |
| Hemosiderin deposition | Total | 0 | 0 | 4 | | 0 | 6 |
| | + | 0 | 0 | 3 | | 0 | 6 |
| | ++ | 0 | 0 | 1 | | 0 | 0 |
| Cecum | | | | | | | |
| Ulcer | Total | 0 | 0 | 4 | | 0 | 0 |
| | + | 0 | 0 | 1 | | 0 | 0 |
| | ++ | 0 | 0 | 2 | | 0 | 0 |
| | +++ | 0 | 0 | 1 | | 0 | 0 |
| Liver | | | | | | | |
| Hypertrophy, hepatocytes, centrilobular | + | 0 | 0 | 4 | | 0 | 0 |
| Testis | | | | | | | |
| Atrophy, seminiferous tubules, diffuse | Total | 0 | 0 | 6 | | 0 | 5 |
| | + | 0 | 0 | 6 | ** | 0 | 2 |
| | ++ | 0 | 0 | 0 | | 0 | 3 |
| Epididymis | | | | | | | |
| Cell debris, lumen | Total | 0 | 0 | 4 | | 0 | 1 |
| | + | 0 | 0 | 3 | | 0 | 1 |
| | ++ | 0 | 0 | 1 | | 0 | 0 |
| Decrease in sperm | Total | 0 | 0 | 6 | | 0 | 3 |
| | + | 0 | 0 | 5 | ** | 0 | 0 |
| | ++ | 0 | 0 | 1 | | 0 | 1 |
| | +++ | 0 | 0 | 0 | | 0 | 2 |
| Females | | | | | | | |
| No. animals examined | 6 | 6 | 6 | 6 | 6 | 6 | |
| Spleen | | | | | | | |
| Development, germinal center | + | 0 | 0 | 5 | * | 0 | 0 |
| Extramedullary hematopoiesis, erythrocyte | + | 0 | 0 | 6 | ** | 0 | 0 |
| Hemosiderin deposition | Total | 0 | 0 | 6 | | 0 | 6 |
| | + | 0 | 0 | 3 | ** | 0 | 6 |
| | ++ | 0 | 0 | 3 | | 0 | 0 |
| Cecum | | | | | | | |
| Ulcer | ++ | 0 | 0 | 3 | | 0 | 0 |
| Liver | | | | | | | |
| Hypertrophy, hepatocytes, centrilobular | + | 0 | 0 | 3 | | 0 | 0 |

Grade sign: +, mild; ++, moderate; +++, marked. †Rats were killed at 7 weeks of age; ‡rats were killed at 9 weeks of age. * $P < 0.05$ and ** $P < 0.01$ indicate significantly different from control group.

newborn rats. The Sertoli cells play an important role in the establishment and maintenance of the specific microenvironment of the adluminal compartment of the seminiferous epithelium and this is a prerequisite for normal spermatogenesis (Sjöberg *et al.* 1986). In rats, Sertoli cells proliferate rapidly from day 19 of gestation to PND 15, then slow down and cease multiplying on approximately PND 20 (Orth 1982, Orth 1984; Toppari *et al.* 1996). The dosing periods were PND 4–21 and postnatal weeks 5–8 in the newborn and young rat studies, respectively. Therefore, TNP seems unlikely to affect the differentiation and proliferation of Sertoli cells, and seems likely to affect the maturation of spermatids, although it remains to be elucidated whether this is a direct effect of TNP or some kind of TNP metabolite.

In conclusion, in the newborn rat study, the NOAEL for TNP were 16.3 mg/kg per day, low BW at 65.1 mg/kg per day or more, and death at 81.4 mg/kg per day were observed. In the young rat study, the NOAEL for TNP were 20 mg/kg per day and hemolytic anemia and testicular toxicity were found at 100 mg/kg per day.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the financial support of the Office of Chemical Safety, Pharmaceutical and Medical Safety Bureau, Ministry of Health, Labor and Welfare, Japan.

REFERENCES

- Bär TH, Wolff JR (1972) The formation of the capillary basement membranes during internal vascularization of the rat's cerebral cortex. *Z Zellforsch* **133**: 231–248.
- Bloom JC, Brandt JT (2001) Toxic responses of the blood. In: Klaassen CD (ed.) *Casarett and Doull's Toxicology: The Basic Science of Poisons*, 6th edn. McGraw-Hill, New York, p397.
- Fomon SJ, Haschke F, Ziegler EE, Nelson SE (1982) Body composition of reference children from birth to age 10 years. *Am J Clin Nutr* **35**: 1169–1175.
- Fukuda N, Ito Y, Yamaguchi M *et al.* (2004) Unexpected nephrotoxicity induced by tetrabromobisphenol A in newborn rats. *Toxicol Lett* **150**: 145–155.
- Health Council of the Netherlands (2002) *Health-based Reassessment of Administrative Occupational Exposure Limits – Picric Acid*. Committee on Updating of Occupational Exposure Limits, a committee of the Health Council of the Netherlands. Health Council of the Netherlands, the Netherlands.
- Imaoka S, Fujita S, Funae Y (1991) Age-dependent expression of cytochrome P-450s in rat liver. *Biochim Biophys Acta* **1097**: 187–192.
- Kearns GL, Reed MD (1989) Clinical pharmacokinetics in infants and children: A reappraisal. *Clin Pharmacokinet* **17**: 29–67.
- Koizumi M, Nishimura N, Enami T *et al.* (2002) Comparative toxicity study of 3-aminophenol in newborn and young rats. *J Toxicol Sci* **27**: 411–421.
- Koizumi M, Noda A, Ito Y *et al.* (2003) Higher susceptibility of newborn than young rats to 3-methylphenol. *J Toxicol Sci* **28**: 59–70.
- Koizumi M, Yamamoto Y, Ito Y *et al.* (2001) Comparative study of toxicity of 4-nitrophenol and 2,4-dinitrophenol in newborn and young rats. *J Toxicol Sci* **26** (5): 299–311.
- Ministry of Health and Welfare Japan (1988) *Standard Concerning Testing Facility Provided in Article 4 of Order Prescribing Test Items Relating to New Chemical Substances and Toxicity Research of Designated Chemical Substances*. Planning and Coordination Bureau, Environment Agency, No. 39, Environmental Health Bureau, Ministry of Health and Welfare, No. 229. Basic Industries Bureau, Ministry of International Trade and Industry, No. 85, March 31, 1984, and amendments, November 18, 1988. MHW, Japan.
- Ministry of Health, Labour, Welfare Japan (2001) 2,4,6-trinitrophenol (88–89–1). *Toxicity Testing Reports Environmental Chemicals*. MHLW, Japan, 8: 238–243.
- National Research Council USA (1993) *Pesticides in the Diets of Infants and Children*. NRC, USA. National Academy Press, Washington DC.
- Organisation for Economic Co-operation and Development (1981) *OECD Principles of Good Laboratory Practice*. OECD, Paris.
- Organisation for Economic Co-operation and Development (1997) *OECD Principles of Good Laboratory Practice* (as revised in 1997). OECD, Paris.
- Orth JM (1982) Proliferation of Sertoli cells in fetal and postnatal rats: A quantitative autoradiographic study. *Anat Rec* **203**: 485–492.
- Orth JM (1984) The role of follicle-stimulating hormone in controlling Sertoli cell proliferation in testes of fetal rats. *Endocrinology* **115**: 1248–1255.
- Reese TS, Karnovsky MJ (1967) Fine structural localization of a blood–brain barrier to exogenous peroxidase. *J Cell Biol* **34**: 207–217.
- Scheuplein R, Charnley G, Dourson M (2002) Differential sensitivity of children and adults to chemical toxicity. *Regul Toxicol Pharmacol* **35**: 429–447.
- Schwenk M, Gundert-Remy U, Heinemeyer G *et al.* (2002) Children as a sensitive subgroup and their role in regulatory toxicology: DGPT workshop report. *Arch Toxicol* **77**: 2–6.
- Sjöberg POJ, Bondesson UG, Sedin EG, Gustafsson JP (1985) Exposure of newborn infants to plasticizers: Plasma levels of di-(2-ethylhexyl) phthalate and mono-

- (2-ethylhexyl) phthalate during exchange transfusion. *Transfusion* 25: 424-428.
- Sjöberg P, Lindqvist NG, Plöen L (1986) Age-dependent response of the rat testes to di-(2-ethylhexyl) phthalate. *Environ Health Perspect* 65: 237-242.
- Toppari J, Larsen JC, Christiansen P *et al.* (1996) Male reproductive health and environmental xenoestrogens. *Environ Health Perspect* 104 (Suppl. 4): 741-803.
- US Environmental Protection Agency (1998) *The EPA Children's Environmental Health Yearbook*. US EPA, Washington DC.
- World Health Organization (1986) *Principles for Evaluating Risks from Chemicals during Infancy and Early Childhood: The Need for a Special Approach*. WHO, Geneva.
- Wyman JF, Serve MP, Hobson DW, Lee LH, Uddin DE (1992) Acute toxicity, distribution, and metabolism of 2,4,6-trinitrophenol (picric acid) in Fischer 344 rats. *J Toxicol Environ Health* 37: 313-327.

REVISION AND ESTABLISHMENT OF JAPANESE DRINKING WATER QUALITY GUIDELINES FOR DI(2-ETHYLHEXYL) PHTHALATE, TOLUENE AND VINYL CHLORIDE — DIFFERENCES FROM THE LATEST WHO GUIDELINE DRAFTS —

Akihiko HIROSE¹, Ryuichi HASEGAWA², Akiyoshi NISHIKAWA³,
Mika TAKAHASHI¹ and Makoto EMA¹

¹*Division of Risk Assessment,*

²*Division of Medicinal Safety Science and* ³*Division of Pathology,*

National Institute of Health Sciences,

1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan

(Received June 23, 2004; Accepted October 7, 2004)

ABSTRACT — The revision of the Japanese drinking water quality guidelines was established in May 2003. The WHO drinking water quality guidelines for the 3rd edition were also revised and the draft has been open to the public since last year. Most guideline values of each chemical in both Japan and WHO were quite similar; however, there are different overt values for three chemicals. In this short communication, we describe them and discuss the reason for taking the different toxicity endpoints and derivation method for these three chemicals, di(2-ethylhexyl) phthalate, toluene and vinyl chloride.

KEY WORDS: Drinking water quality guidelines, Di(2-ethylhexyl) phthalate, Toluene, Vinyl chloride

INTRODUCTION

The revision of the Japanese drinking water quality guideline was established in May 2003 and implemented on May 2004. In this revising, regulated chemical lists were modified because of the past detection trend or exposure prospect. The chemicals already listed in the previous version were reevaluated and chemicals newly listed in this revision were assessed with the latest toxicity information. The Japanese guidelines derivation has referred to the concurrent WHO revision, and both of the general principles for the guidelines (GD) derivation are almost the same. Although most guideline values of chemicals in Japan were similar to those of WHO, some minor differences between WHO and Japan exist because of different default body weight application for the guideline calculation (50 kg/Japan vs. 60 kg/WHO). Furthermore, in some cases, different drinking water contribution ratios (allocation) to total exposure media were used for the guideline values calculation from tolerable daily intake

(TDI) on account of the regional chemical exposure assessment. These differences were not owing to the difference of health risk assessment per se. However, the different guideline values for di(2-ethylhexyl) phthalate (DEHP), toluene and vinyl chloride between the Japanese guidelines revision (2003) and the latest rolling revision of WHO drinking water quality guideline were mainly caused by the health risk assessment variation. In this short communication, we describe the reason for taking the different toxicity endpoints or derivation method of the guidelines. Table 1 shows the guideline values for three chemicals of the WHO 2nd edition (WHO, 1996) established in 1994 and rolling revision in 2003, and previous and present Japanese versions.

DERIVATION OF GUIDELINE VALUES

Di(2-ethylhexyl) phthalate (DEHP)

As the guideline value of DEHP by the WHO 2nd edition, 0.008 mg/L was derived from a no observed

Correspondence: Akihiko HIROSE

adverse effect level (NOAEL) of 2.5 mg/kg/day in a rat feeding study (Morton, 1979) for 7 days according to no induction of hepatic peroxisome proliferation. The hepatic tumors were considered to be the most critical endpoint and hepatic peroxisome proliferation to be closely related to the carcinogenic mechanism. An uncertainty factor of 100 was applied only because of the animal most sensitive to peroxisome proliferation, and the allocation of 1% that was used as DEHP is generally not contained in food (WHO, 1996). For the latest WHO assessment, the guideline value of DEHP was not changed from the 2nd edition, because it was not listed for the detailed reevaluation.

In 1994, the Japanese government decided to use the same data and derivation method for domestic drinking water guidelines except for 10% allocation and 50 kg instead of 60 kg for human body weight. The guideline value was 0.06 mg/L.

However, the Japanese government established a TDI for DEHP in 2001 when high contamination was found in some specific foods and the health risk was deeply concerned (Koizumi *et al.*, 2001). In this assessment, TDI ranging from 40 to 140 μ g/kg/day was established from a NOAEL of 3.7 mg/kg/day for testicular toxicity in a rat study (Poon *et al.*, 1997) and 14 mg/kg/day for reproductive toxicity in a mouse study (Lamb *et al.*, 1987), respectively, applying an uncertainty factor of 100 for intra- and interspecies differences. As for hepatic peroxisome proliferation, it was taken out for extrapolation to humans because IARC (2000) concluded that the hepatic tumor due to DEHP in rodents (in association with peroxisome proliferation) is not relevant to other animal species including humans (Group 3). Although it is clearly shown that there are strong species differences in testicular toxicity such as severely toxic in rats and guinea pigs, weakly in mice but not in hamsters, marmosets and cynomolgus monkeys, the potential of testicular toxicity in humans cannot be excluded at this moment. Therefore, the guideline of 0.1 mg/L was derived from

40 μ g/kg/day of TDI using 10% of allocation, and 2 L of daily water intake for 50 kg body weight of the Japanese population.

Toluene

In 1994, WHO tried to re-assess the toxicity data of toluene and made the same conclusion as the previous value, 0.7 mg/L. A TDI of 0.223 mg/kg/day was derived using the lowest observed adverse effect level (LOAEL) for marginal hepatotoxicity in mice of 312 mg/kg/day (equivalent to 223 mg/kg/day, as there were 5 days per week) (NTP, 1990) and applying an uncertainty factor of 1,000 (100 for inter- and intra-species variation and 10 for the short duration of the study and use of a LOAEL instead of a NOAEL). This TDI yields a guideline value of 0.7 mg/L (rounded figure), allocating 10% of the TDI to drinking-water (WHO, 1996).

The Japanese government used the same data and derivation method for the domestic drinking water guideline except for 50 kg instead of 60 kg for human body weight. The guideline value was established as 0.6 mg/L in 1994.

For the new revision, the Japanese Government used a different toxicity endpoint, neurotoxicity, which is the most typical toxicity for toluene. In the case of neurotoxicity with histopathological changes as well as carcinogenicity and developmental toxicity without maternal toxicity, some additional uncertainty factors should be considered to derive a TDI. Toluene showed neuropathological effects in the brain consisting of neuronal cell necrosis in the dentate gyrus and Ammon's horn of the hippocampus at 1250 and 2500 mg/kg/day. NOAEL for neurotoxicity was 625 mg/kg/day (equivalent to 446 mg/kg/day, as there were 5 days per week) and a TDI of 0.0892 mg/kg/day was derived by application of an uncertainty factor of 5,000 including additional uncertainty factors of 5 for short exposure duration and 10 for neuropathological changes. This TDI yields a guideline value of 0.2 mg/L (rounded figure), allocating 10% of the TDI to drinking-water.

Table 1. Comparison of three guideline values (mg/L) between WHO and Japanese drinking water.

| | WHO Guideline | | Japanese Guideline | |
|----------------|-------------------------------|--|--------------------|-------|
| | 1994 (2 nd ed.) | Revising 2003 (3 rd ed.) | 1994 | 2003 |
| DEHP | 0.008 | 0.008* | 0.06 | 0.1 |
| Toluene | 0.7 | 0.7 | 0.6 | 0.2 |
| Vinyl chloride | 0.005 | 0.0003 | No setting | 0.002 |

*: No detailed reevaluation draft.

Vinyl chloride

It has been generally accepted that a mathematical model such as a linearized multistage is appropriate to estimate a low-dose cancer risk of a genotoxic carcinogen. There is sufficient evidence showing that vinyl chloride is a multiple site carcinogen and its metabolites are genotoxicants. Table 2 shows the incidences of hepatic tumor-related lesions in studies reported by Feron *et al.* (1981) and Til *et al.* (1991).

In the WHO 2nd edition, a linearized multistage model was applied to the incidence of angiosarcomas in female rats which was reported by Feron *et al.* (1981) only because of a good relationship with the human incidence at that time. An excess cancer risk at 10^{-5} was 0.010 mg/L. The guideline value was 0.005 mg/L, applying an uncertainty factor of 2 for double risk by exposure from birth (WHO, 1996).

On the other hand, in the WHO rolling revision, total liver tumors (angiosarcomas, hepatocellular carcinomas and neoplastic nodules) from the same study are incorporated to derive the guideline value including conversion to human equivalent doses (using the physiologically based pharmacokinetic (PBPK) model of U.S. EPA, 2000, Clewell *et al.*, 2001). A linear low-

dose extrapolation was conducted by drawing a straight line between 10% of the low estimate dose (Benchmark dose approach) and the origin (zero dose). The results were nearly identical with those derived using the linearized multistage model. The concentrations in drinking-water of 0.0005 mg/L were calculated as being associated with excess risks of liver tumors of 10^{-5} for lifetime exposure beginning at adulthood. Exposure from birth would double this risk (U.S. EPA, 2000). This would result in a rounded guideline value of 0.0003 mg/L for a theoretical risk of 10^{-5} .

The guideline for vinyl chloride was not set in the previous Japanese guideline.

As described in Table 2, Feron *et al.* (1981) obtained clear evidence of carcinogenicity in rat liver in a three-dose setting study but the low dose of 1.7 mg/kg/day was still carcinogenic in female rats. The same group (Til *et al.*, 1991) conducted a further study up to 0.014 mg/kg/day and showed that the middle dose of 0.13 mg/kg/day was a non-carcinogenic dose. As both studies had been conducted under mostly the same experimental conditions, these data would be considered from a single study with doses ranging 1,000 times. For derivation of the newly established

Table 2. Summary incidence of hepatic tumor-related lesions for two rat carcinogenicity studies conducted by the same group.

| mg/kg/day | Til <i>et al.</i> , 1991 | | | | Feron <i>et al.</i> , 1981 | | | |
|---------------------------------|---------------------------------------|--------------|---------------|-----------------|----------------------------|-------------------|------------------|------------------|
| | 0 | 0.014 | 0.13 | 1.3 | 0 | 1.7 | 5.0 | 14.1 |
| Male | | | | | | | | |
| Neoplastic nodules | 0/99 ^a (0) ^b | 0/99 (0) | 0/99 (0) | 1/49 (2.0) | 0/55 (0) | 1/58 (1.7) | 7*/56 (12.5) | 23*/59 (39.0) |
| Hepatocellular carcinoma | 0/99 (0) | 0/99 (0) | 0/99 (0) | 3*/49 (6.1) | 0/55 (0) | 1/58 (1.7) | 7*/56 (12.5) | 23*/59 (39.0) |
| Angiosarcomas | 0/99 (0) | 0/99 (0) | 0/99 (0) | 1/49 (2.0) | 0/55 (0) | 1/58 (1.7) | 2/56 (3.6) | 8*/59 (13.6) |
| Female | | | | | | | | |
| Neoplastic nodules | 0/98 (0) | 0/100 (0) | 1/96 (1.0) | 9*/49 (18.4) | 2/57 (8.8) | 26**/58 (44.8) | 39*/59 (66.1) | 44*/57 (77.2) |
| Hepatocellular carcinoma | 1/98 (1.0) | 0/100 (0) | 1/96 (1.0) | 3/49 (6.1) | 0/57 (0) | 4*/58 (6.9) | 19*/59 (33.2) | 29*/57 (50.9) |
| Angiosarcomas | 0/98 (0) | 0/100 (0) | 0/96 (0) | 2/49 (4.1) | 0/57 (0) | 0/58 (0) | 2/59 (3.4) | 9*/57 (15.8) |
| Total liver tumors ^c | | | | | 2/57 (8.8) | 28/58 (48.2) | 49/59 (83.1) | 56/57 (98.2) |

^a: Number of lesion-bearing animals / number of analyzed animals.

^b: Percentages of incidences.

^c: The total number of animals with tumors derived from US IRIS(2000) / number of analyzed animals.

Statistically significant compared to the controls with *p<0.05 or **p<0.01 was reported in the original articles.

Japanese guideline value, the neoplastic nodules were not taken into account for the following reasons. As there was no diagnosis of nodular hyperplasia in those reports, there is a possibility that the neoplastic nodules may include not only hepatocellular adenoma but also nodular hyperplasia, which is not considered to be a neoplastic lesion. The high incidence of neoplastic nodules at 1.7 mg/kg/day in females quickly dropped to less than half at 1.3 mg/kg/day and virtually no incidence at 0.13 mg/kg/day. This dose-response may not be appropriate for extrapolation to low doses. The incidence slope of total liver tumors mostly reflected the high incidence of neoplastic nodules rather than the real cancer incidence. In addition, because hepatocellular carcinomas and angiosarcomas originate from different cells, liver and vascular cells respectively, the evaluation of combined incidences may draw a conflicting conclusion. Therefore, the dose-response incidences of hepatocellular carcinoma in female rats were considered to be most appropriate for application to dose-response analysis, in view of data from the two reports. After dose conversion based on the PBPK model, an excess risk of 10^{-5} by the multistage model was calculated to be 0.0875 mg/kg/day as a virtual

safety dose (VSD). The guideline of 0.002 mg/L was derived using 2 L of daily water intake for 50 kg body weight of the Japanese population. The allocation factor was not applied for the mathematical model approach because of large uncertainty caused by highly lower dose extrapolation.

DISCUSSION

Table 3 summarizes the derivation processes of all three chemicals. Although the detailed reevaluation draft for DEHP has not been published in the 3rd WHO water quality guideline, it was presumed that the derivation process would be same as the 2nd edition because were no changed guideline values. The general principle for the derivation of TDI and VSD is the same between Japan and WHO; however, the difference in the choice of critical endpoints leads to varied guideline values. In the Japanese assessment, testicular toxicity of DEHP and neurotoxicity of toluene were used to derive a TDI instead of their hepatotoxicity adopted by WHO. In the case of vinyl chloride, the same critical study was used for the guideline derivation, but the adopted neoplastic endpoints were differ-

Table 3. Summary of guideline value derivation in WHO (3rd ed.) and Japan (2003).

| endpoint | NOAEL (mg/kg/day) | uncertainty factor | | | | TDI or VSD* (mg/kg/day) | allocation (%) | body weight (kg) | water consump. (L) | guideline value (mg/L) | |
|---|----------------------|--------------------|-------------------|-----------------|--|-------------------------------|-------------------|------------------------|--------------------------|------------------------------|-----|
| | | inter- species | intra- species | use of LOAEL | study period nature of toxicity | | | | | | |
| DEHP(WHO) ^a | | | | | | | | | | | |
| hepatic peroxisome proliferation | 2.5 | 10 | 10 | | | 0.025 | 1 | 60 | 2 | 0.008 | |
| DEHP(Japan) | | | | | | | | | | | |
| testicular toxicity | 3.7 | 10 | 10 | | | 0.04 | 10 | 50 | 2 | 0.1 | |
| Toluene(WHO) | | | | | | | | | | | |
| hepatotoxicity | 223 | 10 | 10 | 10 | | 0.223 | 10 | 60 | 2 | 0.7 | |
| Toluene(Japan) | | | | | | | | | | | |
| neurotoxicity | 446 | 10 | 10 | | 5 | 10 | 0.0892 | 10 | 50 | 2 | 0.2 |
| Vinyl chloride(WHO) | | | | | | | | | | | |
| total liver tumors (angiosarcoma, hepatocellular carcinoma and neoplastic nodules) | | | | | | | | | | 0.0003 [†] | |
| Vinyl chloride(Japan) | | | | | | | | | | | |
| hepatocellular carcinoma | | | | | | 0.0875* | | 50 | 2 | 0.002 | |

^a: Derived from the 2nd edition.

[†]: At the initial calculation from experimental animal data, the guideline concentration of 0.0005 mg/L was derived as 10^{-5} excess risk concentration during adulthood. Then the concentration was decreased to half because of doubled risk for exposure from birth.

*: Virtual safety dose corresponding to an excess cancer risk of 10^{-5} .

ent from each other because of the different interpretation on the cancer risk assessment. The adverse effects in experimental animals for the human health assessment are chosen by consideration of appropriate extrapolation to humans, which is expected from the nature of the toxicity, toxicity mechanism, etc. With regard to taking appropriate toxicity endpoints for derivation, the latest Japanese decision is considered to be more suitable on the basis of recent scientific consideration as described before. Because the revisions for the 3rd edition of water quality guidelines in the WHO are still ongoing, the assessment and the guideline value may be changed until the fixed version is published.

As for the derivation of the guideline value from the TDI, the estimation of the exposure contribution ratio (the allocation) is another important issue. In the case of DEHP, both levels of TDIs or NOAELs estimated in Japan and WHO are similar, although the critical endpoints are different. The guideline values were different at one order of degree from each other, because the allocation factor for drinking water of the TDI estimated in WHO was one-tenth of that in Japan. The allocation depends on environmental circumstances as well as chemical physical properties, and local exposure assessment is necessary for the estimation of the allocation factor of the respective chemical. Although the DEHP exposure contribution for drinking water in the WHO 2nd edition was estimated to be considerably lower, the allocation of 10% was applied in Japan as the default value when the exposure assessment was not elucidated.

Given the risk management of drinking water supplied by the Waterworks, the derivation of the guideline values of chemicals may be a regional issue. However, a large amount of drinking water bottled as mineral water has been circulating worldwide and the regulated values of chemicals will also be based on the drinking water guideline. Therefore the need for the international harmonization of chemical risk assessment will be required even more in the future.

REFERENCES

- Clewell, H.J., Gentry, P.R., Gearhart, J.M., Allen, B.C. and Andersen, M.E. (2001): Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. *Sci. Total. Environ.*, **274**, 37-66.
- Feron, V.J., Hendriksen, C.F.M., Speek, A.J., Til, H.P. and Spit, B.J. (1981): Lifespan oral toxicity study of vinyl chloride in rats. *Food Cosmet. Toxicol.*, **19**, 317-333.
- International Agency for Research on Cancer (IARC) (2000): Some industrial chemicals. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume **77**, Lyon, 41-148.
- Koizumi, M., Ema, M., Hirose, A., Kurokawa, Y. and Hasegawa, R. (2001): No observed adverse effect levels of phthalate esters on reproductive and developmental toxicity, the differences with age and species in testicular toxicity, and tolerable daily intake of DEHP. *Jpn. J. Food Chem.*, **8**, 1-10 (Japanese).
- Lamb, J. C.IV, Chapin, R.E., Teague, J., Lawton, A.D. and Reel, J. (1987): Reproductive effects of four phthalic acid esters in the mouse. *Toxicol. Appl. Pharmacol.*, **88**, 255-269.
- Morton, S.J. (1979): The hepatic effects of dietary di-2-ethylhexyl phthalate. Ann Arbor, MI, Johns Hopkins University, 1979 (dissertation; abstract in *Dissertation abstracts international*, 1979, **B 40**, 4236).
- National Toxicology Program (NTP) (1990): Toxicology and carcinogenesis studies of toluene (CAS no. 108-88-3) in F344/N rats and B6C3F1 mice (inhalation studies). NTP Technical Report Series No. 371, US Department of Health and Human Services (NIH Publication No. 90-2826).
- Poon, R., Lecavalier, P., Mueller, R., Valli, V.E., Procter, B. G. and Chu, I. (1997): Subchronic oral toxicity of di-*n*-octyl phthalate and di(2-ethylhexyl) phthalate in the rat. *Food Chem. Toxicol.*, **35**, 2225-2239.
- Til, H.P., Feron, V.J. and Immel, H.R. (1991): Lifetime (149-week) oral carcinogenicity study of vinyl chloride in rats. *Food Chem. Toxicol.*, **29**, 713-718.
- U.S. Environmental Protection Agency (EPA) (2000): Vinyl chloride (CASRN 75-01-4) on Integrated Risk Information System (IRIS). <http://www.epa.gov/iris/> (available only on line)
- World Health Organization (WHO) (1996): Guidelines for drinking-water quality, Volume 2, Health criteria and other supporting information. Second ed., World Health Organization, Geneva.

生殖発生毒性を指標としたダイオキシンの耐容1日摂取量 (TDI) 算定の考え方について

総合評価研究室 広瀬明彦, 江馬 眞

The recent TDI derivation of the dioxin based on the reproductive and developmental toxicity.

Akihiko Hirose and Makoto Ema
Division of Risk Assessment

SUMMARY

In 1998, WHO-IPCS re-assessed the TDI of dioxin, which was derived from the body burdens of TCDD exposed to the experimental animals. Then, the international assessment agencies and governmental assessment agencies have conducted the dioxin health assessment using the similar method to the WHO-IPCS approach. The key endpoints were reproductive and developmental toxicity caused by *in utero* and lactational exposure. Each assessment agencies used the similar data set of the toxicity studies, however, there are some differences about the TDI derivation method and the selection of adverse endpoints. This report reviewed the recent reproductive and developmental toxicity studies of the dioxins and summarized the health assessment in the international or governmental agencies, and discussed the appropriate TDI derivation.

Key Word: dioxin, tolerable daily intake, reproductive and developmental toxicity

はじめに

1998年にWHO-IPCSが、ダイオキシンの体内蓄積性を考慮して体内負荷量という概念を用いて、耐容1日摂取量(TDI)の再評価を行った¹⁾。我が国でも1999年に、体内負荷量を基にしてTDIの設定を行っている²⁾。これ以前は、発がん性を感受性の高いエンドポイントとしてTDIを設定していたが、この体内負荷量という物差しを用いることにより、胎児期及び授乳暴露による次世代への影響がより感受性の高い毒性指標となることが明らかになった。その結果、これ以降はヨーロッパ各国やJECFAなどの評価機関では、この評価法に従い耐用摂取量評価を算定してきている。本研究では、この評価法の重要なエンドポイントであるダイオキシン類による生殖発生毒性に関して、1998年以降の新しい知見と、各国および国際評価機関でのTDI算定経過をまとめると共に、現時点での適切なTDIのあり方について考察した。

体内負荷量とTDI

まず、体内負荷量を用いたTDIの算定法について概略を示す。一般に化学物質の耐用摂取量は、最も感受性の高い毒性学的エンドポイントを基に算定される。ヒトを対象とした定量的で信頼性の高い疫学研究などの知見がある場合はそれを用いるが、通常は疫学上の交絡因子を完全に排除することは難しく、動物実験における化学物質の投与用量を基に、ヒトにおける耐用摂取量を算出している。1990年代の前半頃まではダイオキシンに関して最も感受性の高い毒性は、げっ

歯類に対する発がん性であると考えられており、評価機関の多くは、ラットを用いた2年間の長期投与試験における無毒性量(NOEL):1ng/kg/dayを基に、不確実係数(多くは100)を適用して耐容1日摂取量を設定していた。しかし、1998年のWHO-IPCS¹⁾での評価以後は、ダイオキシン類のように脂溶性が高く、排泄が遅い物質は、長い時間をかけて徐々に体内に化学物質が蓄積していくことや、ヒトとラットでは数百倍も排泄速度が異なることから、投与量と蓄積濃度(=体内負荷量)と関係はヒトとラットで著しく異なることになり、投与量をベースにして毒性発現を比較するのは適当ではないと判断された。また、ダイオキシン類による毒性発現は蓄積量である体内負荷量に依存して発現していることが示され、近年は、この体内負荷量を基に定量的な毒性評価を行うようになった。この体内負荷量という物差しを用いることにより、従来の発がん性よりも、胎児期及び授乳期暴露による次世代への影響がより感受性の高い毒性指標となることが明らかになった。この際、摂取量と体内負荷量との換算は、1コンパートメントモデルの定常状態における、以下の近似式で示すことができる。

$$\text{摂取量(ng/kg/day)} = [\text{体内負荷量(ng/kg)} \times \ln(2)] / [\text{半減期(day)} \times \text{吸収率}]$$

また、ヒトや実験動物に関する様々な知見より、ヒトと実

験動物では同じ体内負荷量で毒性が発現すると判断されている。したがって、TDIを求めるには、まず動物実験において最も低い体内負荷量で発現するエンドポイントを選定し、その体内負荷量においてはヒトでも同様の影響が現れると仮定する。その後、上記の式からその体内負荷用に相当するヒトにおける1日摂取量を算出し、この値に対して不確実係数を適用して、TDIを算定するという手順を踏むことになる。

ダイオキシン類による生殖発生毒性

1998年以降に公表された2,3,7,8-四塩化ジベンゾパラジオキシン(TCDD)の生殖発生毒性に関する論文の内容について検討した(Table 1)。

SDラットの妊娠15日に200または1000 ng/kgのTCDDを単回強制経口投与したところ⁹⁾、両TCDD投与群で母体体重が低下し、1000 ng/kg投与群では出生児数の減少がみられたが、雄児の成長にはTCDD投与の影響は観察されなかった。雄児の生後30日において1000 ng/kg投与群で17-βヒドロキシラーゼ活性及び精巣上体重量の低下、生後45日に精巣の3β-及び17β-ヒドロキステロイドデヒドロゲナーゼ、5α-リダクターゼ活性上昇及び血清中アンドロゲン濃度の低下が認められた。

Holtzmanラットの妊娠15日に250 ng/kgのTCDDを単回強制経口投与した¹⁰⁾ときには、TCDD投与の雄児に精巣上体精子数の減少、前立腺重量の低下が観察されたが、肛門生殖突起間距離(AGD)、性成熟、精巣の1日精子産生、精巣重量及び前立腺を除く副生殖器重量にTCDD投与の影響は認められなかった。

Holtzmanラットの妊娠15日に1000 ng/kgのTCDDを単回強制経口投与した⁹⁾ところ、投与後4日の雌胎児でミューラー管尾部の間充織の肥厚、ミューラー管癒合の阻害、ウラルフ管退行の阻害が観察され、これらが永久的なvaginal thread(膈糸)の原因であることが示唆された。

Long Evansラットの妊娠15日に1000 ng/kgのTCDDを単回強制経口投与し¹¹⁾、雄児の精囊について調べた。雄児体重及び精囊重量には生後32日までTCDD投与群と対照群との間に差はみられなかったが、49日以降ではTCDD投与群において低下が認められた。TCDD投与群では精囊上皮の分岐及び分化を低下させることによって、精囊の発生を傷害することが示唆された。

Syrianハムスターの妊娠11.5日に2000 ng/kgのTCDDを強制経口投与した¹²⁾ところ、母体の生存率及び体重、児数にTCDD投与の影響はみられなかったが、TCDD投与群のF1児の体重増加抑制、陰開口遅延、膈性周期の変化が認められた。雌F1では陰核の完全分裂が観察されたが、vaginal threadは観察されなかった。雌F1を無処置の雄と交配させたところ、TCDD投与群で妊娠率低下し、妊娠ハムスターの死亡率上昇、分娩生存児数減少、離乳率低下が観察された。これ

らの結果から、妊娠母体に有害な作用を示さない投与量のTCDDが雌児の成長、繁殖機能、生殖器の形態に悪影響を及ぼすことが明らかになった。

雌Wistarラットに25、60または300 ng/kgのTCDDを交配前2週に皮下投与し、交配前、交配中、妊娠中及び授乳中を通じて、5、12または60 ng/kgのTCDDを週1回皮下投与した¹¹⁾。300/60 ng/kg投与群で母ラットの妊娠率が低下し、雄児の血清中テストステロン濃度の低下が認められた。全TCDD投与群の雄児で精巣上体の精子数、精巣の1日精子産生及び精子通過率の低下、異常精子割合の上昇、性行動の異常が観察されたが、1日精子産生以外のエンドポイントに明らかな用量-反応関係はみられなかった。最小毒性量は25/5 ng/kg(0.8 ng/kg/dayに相当)であった。

Holtzmanラットの妊娠15日に12.5、50、200または800 ng/kgのTCDDを単回強制経口投与したときの児に対する影響の検討が国立環境研究所で行われた。50 ng/kgで生後63及び120日における雄児のAGDが短縮し、12.5 ng/kgで生後120日の腹側前立腺重量が減少した⁹⁾。生後2、49または63日に雄児を検査したところ、800 ng/kgでAGDの短縮がみられたが、1日精子産生及び精巣上体尾部の精子保有に差は認められなかった¹⁰⁾。生後49または120日の検査結果では、200 ng/kg以上で腹部前立腺重量の低下が観察され、50 ng/kg以上で生後120日において雄児のAGDが短縮したが、精巣の重量及び組織病理学的検査、1日精子産生、精巣上体重量、精巣上体尾部の精子保有、血清ホルモンレベルにTCDD投与の影響は認められなかった¹¹⁾。また、生後49日の雄児の腹側前立腺において200 ng/kg以上で5α-reductase type 2 mRNAレベルの上昇、50 ng/kg以上でandrogen receptor mRNAレベルの低下が観察された¹¹⁾。生後5日の雄児の胸腺のCYP1A1 mRNA inductionが200 ng/kg以上でみられている(1群3例の実験であり統計処理については不明)が、胸腺の重量及び細胞数には800 ng/kgでもTCDDの影響は観察されなかった¹²⁾。

Long Evansラットの妊娠15日に800 ng/kgのTCDDを投与したとき、雄児の交尾行動の変化が示されている¹³⁾。また、妊娠15日のLong Evansラットに100、300または1000 ng/kgのTCDDを単回強制経口投与し、F4の離乳まで観察したところ、F1において1000 ng/kgで雄児の前立腺重量の低下及びテストステロンレベルの低下、雌児の子宮及び卵巣重量の低下がみられたが、AGD、精子指標、雌性成熟、繁殖指標にはTCDDの影響は認められず、F2以降に生殖に対する影響は観察されなかった¹⁴⁾。

妊娠18日に20、60または180 ng/kgのTCDDを単回強制経口投与したHoltzmanラットの雌児における回転かごでの行動変化が180 ng/kgで認められている¹⁵⁾。

Table 1. Summary of the reproductive and developmental effects by TCDD (published after 1988)

| Species (strain) | Exposure method | Dose (mg/kg) | Reproductive and developmental effects on offspring (no effect) |
|------------------|--|-----------------------------|---|
| rat (SD) | single gavage on day 15 of pregnancy | 200, 1000 | decreased number of pups delivered and decreased pup body weight at 1000 mg/kg |
| rat (Holtzman) | single gavage on day 15 of pregnancy | 250 | decreased sperm number and prostate weight (no effect on age at maturity, litter size, sexual maturation, daily sperm production, weight of uterine accessory reproductive organs) |
| rat (Holtzman) | single gavage on day 15 of pregnancy | 10, 100 | altered vaginal morphogenesis |
| rat (Long Evans) | single gavage on day 15 of pregnancy | 1000 | decreased uterine vesicle weight, decreased uterine vesicle epithelial thickness and differentiation |
| hamster (Syria) | single gavage on day 15 of pregnancy | 2000 | delayed vaginal opening, altered estrous cycles, death in the pregnant F1 females near-term, decreased number of implants and F2 pups born live |
| rat (Wistar) | single s.c. injection at 2 weeks (once in mating, repeated 3 times once a week until end of lactation) | 25, 100, 500 15, 12, 500 | decreased daily sperm production in all dose decreased sperm number, delayed time of the sperm pass through the cauda epididymis, increased abnormal sperm, abnormal sexual behavior (no dose related effects) |
| rat (Holtzman) | single gavage on day 15 of pregnancy | 12.5, 50, 200, 500 | decreased AF150 more than 50 mg/kg decreased uterine vesicle weight more than 200 mg/kg (no effects on daily sperm production, epididymis weight, sperm number) |
| rat (Long Evans) | single gavage on day 15 of pregnancy | 500 | abnormal sexual behavior in male |
| rat (Long Evans) | single gavage on day 15 of pregnancy | 100, 500, 1000 | decreased prostate, uterus and ovary weights in F1 at 1000 mg/kg (no effects on AF150, sperm number, sexual maturation in F1, no effects on all reproductive endpoints in F2 or F3) |
| rat (Holtzman) | single gavage on day 15 of pregnancy | 20, 100, 500 | altered spermatid reorganizing for mature spermatozoa at 100 mg/kg |

1998 年以降の国際機関および各国のダイオキシン評価

1998 年 WHO-IPCS で行われたダイオキシン類の TDI 再評価以後、我が国を始め各国政府及び国際機関でダイオキシン類の健康影響評価と耐容摂取量の勧告状況について以下にまとめた (Table 2)。

1998 年の WHO-IPCS 専門家会合では、上述したように TCDD の半減期がヒトとげっ歯類では著しく異なることから、体内負荷量という概念を用いてヒトへの換算を行い、ヒトの体内負荷量から 1 日摂取量を逆算した後、TDI として 1~4 pg TEQ/kg/day を勧告した。このとき、算出の基となった最も低い体内負荷量で現れる毒性としては、サルにおける子宮内膜症及び神経行動学的発達への影響とげっ歯類の経胎盤/経母乳暴露による次世代の生殖器官発生異常・免疫抑制であり、最低毒性発現体内負荷量としては 28~73 ng/kg と見積もられた。WHO-IPCS ではこれらの毒性のうちどれかを TDI 算定の根拠とするわけではなく、レンジとして捉え幅のある TDI を勧告することになった⁹⁾。

我が国では 1999 年、厚生省と環境庁の合同専門家会合 (中央環境審議会環境保健部会、生活環境審議会、食品衛生調査会) において、WHO-IPCS¹⁾ の考え方を基本とし、TCDD による各種毒性影響を体内負荷量の基準とし、結果として数種の経胎盤/経母乳暴露による次世代の生殖器官発生異常・免疫抑制に関する報告を TDI の算定根拠として選択した。その際、最も低い体内負荷量を示したのは Faqi ら⁸⁾ の報告で 27 ng/kg、次に Ohsako ら¹⁰⁾ (当時は学会発表時のデータを引用した) の 43 ng/kg であったが、それらの単報での値を採用するのではなく、実験の信頼と再現性を考慮し、その他の同様の毒性を比較すると、概ね 86 ng/kg 以上で影響が現れるとすることが妥当であると判断した。また、このときサルの子宮内膜症と神経行動学的発達への影響の実験は、その実験方法に信頼性が担保できないので定量的評価には用いないこととした。その結果、体内負荷量 86 ng/kg を

TDI 算定の出発点とし、不確実係数 10 を用いて、TDI を 4 pgTEQ/kg/day とした²⁾。

米国 EPA の 2000 年の再評価ドラフトでは、ダイオキシン類の最適な毒性指標は発がん性にあるとし、動物実験及びヒトの疫学情報から導き出された体内負荷量をもとに発がん性のリスクを計算した。その結果、1 pgTEQ/kg/day あたりの発がんリスクは 1000 分の 1 であるとし、現在のバックグラウンドレベルの暴露におけるリスクは 100~1000 分の 1 の間にあると算出した。また、本来なら計算されるであろう耐容摂取量に相当する Reference dose については、ヒトのバックグラウンドレベルを大きく下回ることから算出せず、WHO-IPCS で評価した 1~4 pgTEQ/kg/day という TDI はリスクマネジメントの目的としては妥当であるとしている¹¹⁾。

EC の Scientific Committee on Food (SCF) が 2000 年 11 月に行ったダイオキシン類評価では、WHO-IPCS¹⁾ での評価と同様に、体内負荷量の概念を用い、最低体内負荷量のエンドポイントとして、サルにおける子宮内膜症及び神経行動学的発達への影響とげっ歯類の経胎盤/経母乳暴露による次世代の生殖器官発生異常・免疫抑制を取りあげた。このときの体内負荷量は 25~60 ng/kg (WHO-IPCS¹⁾) と同じデータセットを用いているが、主に体内吸収率を 60% と少し低めに設定していることや、単回投与の実験結果を亜慢性試験の実験で得られる結果と比較できるように補正しているため異なった値となっている) と見積り、不確実係数 9.6 から TDI としては 1~3 pgTEQ/kg と計算した。SCF ではこのレンジで与えられた TDI の中から単一の値を採用する科学的根拠に乏しいことから、暫定的な TDI としては、1 pgTEQ/kg にすべきであるとの結論になった。しかし、ダイオキシン類の長い体内残留性を考慮して、1 週間単位の耐容摂取量として 7 pgTEQ/kg/week (t-TWI: temporary tolerable weekly intake) を勧告することになった¹²⁾。しかし、2001 年 5 月には、新たに公表された報告も加え、暫定値の見直しを行った。新たに、Faqi ら⁸⁾ と Ohsako ら¹⁰⁾ のデータを追加し、最低毒性発現体内負荷量として 40~100 ng/kg、無毒性体内負荷量として 20 ng/kg をそれぞれ算出した。無毒性体内負荷量から TDI を算出すると、3 pgTEQ/kg/day となるが、Faqi ら⁸⁾ の Wistar ラットを用いた方が、感受性が高いと考えられ、40 ng/kg から TDI を算出すると 2 pgTEQ/kg/day となった。前回の評価ではサルの試験も感受性の高いエンドポイントとして取りあげられていたが、試験の信頼問題が解決できなかったため、今回は考慮しなかった。さらに、最終的には、前回と同様、長い体内消失半減期を考慮し、1 週間耐容摂取量として 14 pgTEQ/kg/week を勧告した¹³⁾。

2001 年 6 月に行われた FAO と WHO の合同食品添加物専門家会議では、EC-SCF¹²⁾ での再評価と同様のデータセットを用いて、評価を行ったが、耐容摂取量としては体内中の長い半減期を理由に、EC の評価より長い耐容 1 ヶ月許容量

(TMI) を勧告した。算定根拠となる体内負荷量としても SCF の評価と同様に最低毒性発現体内負荷量 (Faqi ら⁸⁾ のデータと無毒性体内負荷量 (Ohsako ら¹¹⁾ のデータを基に計算を行ったが、その際の慢性投与に対する補正を行った体内負荷量の計算方法は、Linear fit model (直線回帰モデル) と Power fit model (べき乗回帰モデル) という 2 つの方法を試みている。それらの結果をもとに SCF と同様の TMI を算出すると 40~100 pg TEQ/kg/month の範囲になり、暫定 TMI としては中間値を取って、70 pgTEQ/kg/month を勧告した¹⁰⁾。

英国の UK-Food Standards Agency (FSA) では EC-SCF¹⁰⁾ 及び JECFA¹⁰⁾ の考え方を基本的に採用した、最も感受性の高いエンドポイントとして、ラット雄への生殖機能の発生異常 (特に精子形成への影響) を用いているが、体内負荷量の算定は、EC-SCF¹⁰⁾ や JECFA¹⁰⁾ とは異なり、最も感受性が高い時期を妊娠 16 日とし、この時期の胎児の体内負荷量と母体の体内負荷量との比を用いて単回投与と反復投与で得られる体内負荷量の値の補正を行った。その結果、Faqi らのデータに基づいて得られた妊娠 16 日の母体の体内負荷量は 33 ng/kg/day と見積もられた。この値から EC-SCF 及び JECFA と同様の不確定係数 (9.6) を用いて TDI として 2 pgTEQ/kg/day を勧告した。EC-SCF¹⁰⁾ や JECFA¹⁰⁾ では 1 週間や 1 ヶ月あたりの耐容量として勧告しているが、TDI として表現する方が適切で、わかりやすいとする理由で、TDI での勧告値を採用しているが、仮に短期間で TDI を越える暴露があっても体内負荷量が大きく変動することはなく、長期間に

例えば、SCF¹⁰⁾ には低い体内負荷量で発現する TCDD の影響として、Holtzman ラットの雄児において 64 ng/kg 以上の投与量で観察された 1 日精子産生低下及び精巣上体精子数の減少²¹⁾、Long Evans ラットの雄児において 50 ng/kg 以上の投与量で観察された開眼促進及び射精精子数減少²²⁾、Wistar ラットの雄児において 25/5 ng/kg 以上の投与量で観察された 1 日精子産生低下及び性行動の変化⁸⁾、Holtzman ラットの雄児において 50 ng/kg 以上の投与量で観察された AGD 短縮¹¹⁾ が記載されている。

Gray ら²²⁾ の報告した開眼促進は 1 日程度の遅れであり、毒性学的意義は弱いと考えられる。また、射精精子数についてはこの実験結果で有意な減少は最高投与量の 800 ng/kg だけに認められたものであり、前報²³⁾ の成績と合わせて統計処理すると 50 ng/kg 以上で有意差が認められたと云う結果である。これらの成績を TDI 設定の根拠とすることは不適切と考えられる。

Faqi ら⁸⁾ の報告した雄児の性行動の変化には用量-反応関係は認められない。

Ohsako ら^{9,11)} により雄児の AGD 短縮が報告されている。AGD の体重による補正值 (AGD/cube root of body weight) は示されておらず、AGD 短縮の程度は軽度であり、児の生後 63 日⁹⁾ と生後 120 日¹¹⁾ に断続的に認められた変化であり、毒性学的な意義は弱いと考えられる。

TCDD の精子細胞、精子に対する影響については多くの報告があるが、TCDD の精子細胞、精子に対する TCDD の影響には報告間で差がみられる。Ohsako ら^{9,10,11)} は精子指標及び精巣の病理組織学的所見には 800 ng/kg までの TCDD 投与の影響は認められなかったとしている。米元ら¹⁴⁾ は 1000 ng/kg の TCDD 投与でも精子検査において TCDD の影響は認められず、同様なプロトコールによる Holtzmann ラット^{21,24,25)} 及び Long Evans ラット^{22,26)} を用いて行われた実験結果を再現できなかったと述べている。Gray ら²³⁾ は精巣の精子産生は TCDD の鋭敏な指標ではないと述べており、また、Theobald と Peterson²⁷⁾ はラット、ハムスター、マウスの 3 種の動物で観察される唯一の生殖発生毒性のエンドポイントは精巣上体の精子数減少であると述べている。このように、低用量の TCDD の精子指標 (1 日精子産生、精巣上体精子数) に対する影響については実験間で整合性のある結果は得られていない。

一方、JECFA¹⁰⁾ の評価でも Faqi ら⁸⁾ や Ohsako ら¹¹⁾ の両報告を用いて様々な体内負荷量の計算を試みているが、結局、どちらか単一の報告を基にするのではなく、両報告から得られた体内負荷量のレンジの中央値を TDI 算定の出発点としたことから、この両報告に対する毒性学的意義付けは必ずしも確定していないと考えられる。また、Rier ら²⁸⁾ および Scantz & Bowman²⁹⁾ のアカゲザルにたいする影響も、1999 年以後、未だにその実験の信頼性に関する問題は依然解決されていなく、EC、JECFA、UK における耐容摂取量

Table 2. Summary of tolerable intake derivations for TCDD in the assessment agencies

| Assessment Agency | Endpoint or effect | Body burden (ng/kg) | Low-dose human intake | Uncertainty factor | Tolerable intake |
|-------------------|--|----------------------|--|--------------------|------------------------------------|
| WHO/PCS | decreased sperm count (male), sperm suppression (male), increased period multiparasites in female (male), neurobehavioral effects (neurotoxic) | 24-73 | 14 pg/kg/day 25 pg/kg/day 37 pg/kg/day 21 pg/kg/day | 10 | 2.1 pg/kg/day |
| Japan | decreased sperm count (male), increased period multiparasites (male), sperm suppression (male) | 66-43 | 6 pg/kg/day | 10 | 2 pg/kg/day |
| EC-SCF | decreased sperm production (male) | 40 | 20 pg/kg/day | 9.6 | 14 pg/kg/day 62 pg/kg/month |
| JECFA | decreased sperm production (male), decreased spermatid diameter in male (male) | 28 or 47 16 or 22 | 423 or 650 pg/kg/month 237 or 370 pg/kg/month | 9.6 3.2 | 2 pg/kg/day 144-103 pg/kg/month |
| UK-FSA | decreased sperm production in rat | 23 | 17 pg/kg/day | 9.6 | 2 pg/kg/day |

わたった平均値が TDI を下回れば有害影響が現れることはないであろうということが付け加えられている²⁰⁾。

まとめ

最近の EC、JECFA、UK のダイオキシン類評価では使用されているデータセットは、1999 年に我が国で行われた再評価で用いられたものほぼ同じであるが、Faqi ら⁸⁾ の 1 日精子産生低下や Ohsako ら¹¹⁾ の雄児の AGD 短縮の報告が最も感受性の高いエンドポイントであるとして体内負荷量を計算し、TDI 算定のための出発点として使用している。た